<SEC-DOCUMENT>0001157523-15-002465.txt : 20150723
<SEC-HEADER>0001157523-15-002465.hdr.sgml : 20150723
<ACCEPTANCE-DATETIME>20150723070015
ACCESSION NUMBER:		0001157523-15-002465
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150723
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150723
DATE AS OF CHANGE:		20150723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGENUS INC
		CENTRAL INDEX KEY:			0001098972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				061562417
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29089
		FILM NUMBER:		151001160

	BUSINESS ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-674-4410

	MAIL ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIGENICS INC /DE/
		DATE OF NAME CHANGE:	19991115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51147783.htm
<DESCRIPTION>AGENUS INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 12pt; font-family: Times New Roman"><br style="font-size: 12pt; font-family: Times New Roman"></font><font style="font-size: 12pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 18pt; font-family: Times New Roman"><b>FORM 8-K</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>CURRENT
      REPORT</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Section 13 or 15(d) of</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>
      the Securities Exchange Act of 1934</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">July
      23, 2015</font><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported)</font><br><br>
    </p>
    <hr style="color: #000000; width: 100%; height: 1.0 pt; text-align: center">


    <p style="text-align: center">
      <font style="font-size: 14pt"><b>AGENUS INC.</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font><br><br><br>
    </p>
    <hr style="color: #000000; width: 100%; height: 1.0 pt; text-align: center">

<div style="text-align:left">

    <table style="margin-bottom: 10.0px; width: 100%; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>DELAWARE</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 34%; text-align: center; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>000-29089</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 33%; text-align: center; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>06-1562417</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (State or other jurisdiction
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            of incorporation)
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 34%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (Commission
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            File Number)
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (IRS Employer
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 50%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>3 Forbes Road</b>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Lexington, MA</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 50%; text-align: center; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>02421</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 50%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices)</font>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 50%; text-align: center" valign="bottom">
          <font style="font-size: 10pt; font-family: Times New Roman">(Zip
          Code)</font>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>781-674-4400</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman">(Registrant&#8217;s
      telephone number, including area code)</font>
    </p>
    <p>

    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p>
      <br>
      Check the appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see General Instruction A.2. below):<br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font><br>
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 7%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 2.02</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 2%; text-align: left" valign="top">
          &#160;
        </td>
        <td style="padding-left: 0.0px; width: 91%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Results of Operations and Financial Condition.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 91%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 7%; text-align: left" valign="top">

        </td>
        <td style="padding-left: 0.0px; width: 2%; text-align: left" valign="top">

        </td>
        <td style="padding-left: 0.0px; width: 91%; text-align: left" valign="top">
          On July 23, 2015, Agenus Inc. announced its financial results for
          the quarter ended June 30, 2015. The full text of the press release
          issued in connection with the announcement is being furnished as
          Exhibit 99.1 to this current report on Form 8-K.
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 91%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 7%; text-align: left" valign="top">

        </td>
        <td style="padding-left: 0.0px; width: 2%; text-align: left" valign="top">

        </td>
        <td style="padding-left: 0.0px; width: 91%; text-align: left" valign="top">
          The information set forth under Item 2.02 and in Exhibit 99.1
          attached hereto is intended to be furnished and shall not be deemed
          &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of
          1934 or otherwise subject to the liabilities of that section, nor
          shall it be deemed incorporated by reference in any filing under the
          Securities Act of 1933, except as expressly set forth by specific
          reference in such filing.
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 91%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 7%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 9.01</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 2%; text-align: left" valign="top">

        </td>
        <td style="padding-left: 0.0px; width: 91%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Financial Statements and Exhibits.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="font-size: 10pt; margin-left: 30.0px">
      &#160;&#160;&#160;&#160;&#160;(d) Exhibits
    </p>
    <p style="font-size: 10pt; margin-left: 30.0px">
      &#160;&#160;&#160;&#160;&#160;The following exhibit is furnished herewith:
    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 9%; text-align: left" valign="top">
          &#160;
        </td>
        <td style="padding-left: 0.0px; width: 91%; text-align: left" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1&#160;&#160;&#160;Press Release dated July 23, 2015
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="font-size: 10pt; margin-left: 90.0px">

    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the Registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 78%">

        </td>
        <td style="padding-left: 0.0px; text-align: right" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>AGENUS INC.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 78%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 78%; text-align: left; padding-bottom: 2.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Date: July 23, 2015
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left; padding-bottom: 2.0px" valign="top">
          By:
        </td>
        <td style="padding-left: 0.0px; width: 17%; border-bottom: solid black 1.0pt; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ C. Evan Ballantyne
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 78%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" colspan="2" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 78%">

        </td>
        <td style="padding-left: 0.0px; text-align: right" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            C. Evan Ballantyne
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 78%">

        </td>
        <td style="padding-left: 0.0px; text-align: right" colspan="2" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Executive Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: left">
      EXHIBIT INDEX<br><br>
    </p>
<div style="text-align:left">
    <table style="width: 100%; margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 12%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Exhibit No.</u>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          &#160;
        </td>
        <td style="padding-left: 0.0px; width: 83%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Description of Exhibit</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 12%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-left: 0.0px; width: 83%; text-align: left" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 12%; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-left: 0.0px; width: 83%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release dated July 23, 2015
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51147783ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Agenus
      Reports Second Quarter 2015 Financial Results</b></font>
    </p>
    <p style="white-space: nowrap; text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Corporate
      Update Conference Call at 11 am ET Today</b></font></i>
    </p>
    <p>
      LEXINGTON, Mass.--(BUSINESS WIRE)--July 23, 2015--Agenus Inc.
      (NASDAQ:AGEN), an immunology company discovering and developing
      innovative treatments for cancers and other diseases,&#160;today announced
      its financial results for the second quarter ended June 30, 2015.
    </p>
    <p>
      &#8220;During the second quarter, we made meaningful advances across all areas
      of our business which include our proprietary clinical-stage programs,
      our immuno-oncology portfolio, strategic acquisitions and our balance
      sheet,&#8221; said Dr. Garo H. Armen, Chairman and CEO of Agenus. &#8220;Of note, we
      presented updated Phase 2 results at ASCO for our autologous heat shock
      protein vaccine, Prophage, in newly diagnosed glioblastoma multiforme,
      demonstrating impressive median overall survival for patients with low
      levels of PD-L1 on their monocytes at baseline, compared to historical
      standard of care data. Our recent acquisition of novel CEACAM1
      antibodies reflects our continued commitment to build a broad, yet
      complementary, portfolio of immuno-modulators with the potential to
      create best-in-class combination therapies for the treatment of cancer.
      This was preceded by our acquisition in April of the SECANT<sup>&#174;</sup>
      yeast display platform from Celexion, a platform which is complementary
      to our Retrocyte Display<sup>TM</sup> platform, and which will allow us
      to enhance the speed and efficiency of our antibody generation. We
      expanded our management team including the addition of Evan Ballantyne
      as our CFO, and we successfully raised $74.6 million in net proceeds
      from a public offering in May to support further development of our
      programs. Looking ahead, we are on track to deliver on our milestones
      for 2015, including the filing of two IND&#8217;s for check point modulator
      programs by year end and advancing Prophage into a Phase 3 study in
      newly diagnosed glioblastoma.&#8221;
    </p>
    <p>
      <b>Second Quarter 2015 Financial Results</b><br>The company reported a
      net loss attributable to common stockholders of $40.5 million, or $0.53
      per share, basic and diluted, for the second quarter ended June 30, 2015
      compared with a net loss attributable to common stockholders for the
      second quarter of 2014 of $7.8 million, or $0.12 per share, basic and
      diluted.
    </p>
    <p>
      For the six months ended June 30, 2015, the company reported a net loss
      attributable to common stockholders of $59.3 million, or $0.83 per
      share, basic and diluted, compared with a net loss attributable to
      common stockholders of $8.5 million, $0.15 per share, basic and diluted,
      for the six months ended June 30, 2014.
    </p>
    <p>
      The increase in net loss attributable to common stockholders for the six
      months ended June 30, 2015, compared to the net loss attributable to
      common stockholders for the same period in 2014, was primarily due to
      the advancement of the check point modulator programs, the $20.7 million
      non-cash expense from fair value adjustments of the contingent
      obligations and the $13.2 million charge for the purchase of the SECANT
      yeast display platform in 2015. During the same period in 2014, the
      company recorded non-cash non-operating income of $11.0 million related
      to the fair value adjustment of a contingent obligation.
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Cash, cash equivalents and short-term investments were $139.6 million as
      of June 30, 2015.
    </p>
    <p>
      <b>Second Quarter 2015 and Recent Corporate Highlights</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        In July, Agenus announced the acquisition of novel antibodies
        targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1)
        from Diatheva s.r.l., an Italian biotech company controlled by SOL
        S.pA.
      </li>
      <li style="margin-bottom: 10.0px">
        In June, Agenus announced the appointment of C. Evan Ballantyne as the
        Company&#8217;s Chief Financial Officer.
      </li>
      <li style="margin-bottom: 10.0px">
        In June, Merck and Agenus extended the research term of their existing
        collaboration and licensing agreement by one year to April 2016,
        allowing Agenus to discover and optimize fully human antibodies
        against two undisclosed Merck checkpoint targets.
      </li>
      <li style="margin-bottom: 10.0px">
        At the 2015 ASCO meeting in June, Orin Bloch, M.D. presented updated
        Phase 2 survival data for Prophage, Agenus&#8217; individualized heat shock
        protein-based cancer vaccine, in newly diagnosed Glioblastoma
        Multiforme (GBM) patients. In patients who had less PD-L1 expression
        on their white blood cells (monocytes) at baseline, the median Overall
        Survival was approximately 45 months, with more than one-third of
        these patients alive without progression for more than three years.
      </li>
      <li style="margin-bottom: 10.0px">
        In May, the company completed a public offering of 12,650,000 shares
        of common stock, offered at $6.30 per share, which includes the
        exercise in full by the underwriters of their option to purchase
        1,650,000 additional shares of common stock. The offering resulted in
        net proceeds in of $74.6 million.
      </li>
      <li style="margin-bottom: 10.0px">
        In April, Agenus acquired the SECANT&#174; yeast display platform for the
        generation of novel monoclonal antibodies from Celexion LLC, a
        privately held biotech company in Cambridge, MA. The acquired assets
        also include Celexion&#8217;s novel approaches to generate antibodies
        against membrane bound protein targets such as G protein&#8211;coupled
        receptors and ion channels, which will be used to assess antibody
        binding and help determine functional attributes of agonist and
        antagonist antibodies in a highly efficient manner.
      </li>
      <li style="margin-bottom: 10.0px">
        In April, primary and secondary endpoint data from GlaxoSmithKline&#8217;s
        (GSK) successful Phase 3 trial of HZ/su, a vaccine candidate for the
        prevention of shingles in adults age 50 or over, were simultaneously
        presented at the 25th Scientific Conference of the European Society of
        Clinical Microbiology and Infectious Disease in Copenhagen, and
        published in the&#160;<i>New England Journal of Medicine.</i> GSK&#8217;s
        HZ/su incorporates Agenus' QS-21 Stimulon&#174; adjuvant, which is designed
        to increase immune response to antigens. The vaccine demonstrated a
        97.2% rate of prevention of the onset of shingles in the study
        population over four years.
      </li>
      <li style="margin-bottom: 10.0px">
        In April, final results from the successful Phase 3 study of GSK&#8217;s
        malaria vaccine candidate, RTS,S, which also incorporates QS-21
        Stimulon, were published in <i>The Lancet.</i>
      </li>
    </ul>
    <p>
      <b>Target Milestones for 2015</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Submission to a peer reviewed journal of the Phase 2 data for Prophage
        in newly diagnosed GBM. Advancement of Prophage for newly diagnosed
        GBM to a Phase 3 trial.
      </li>
      <li style="margin-bottom: 10.0px">
        EMA regulatory decision on GSK&#8217;s&#160;malaria vaccine candidate RTS,S,
        which contains Agenus&#8217;s QS-21 Stimulon. Agenus is eligible to receive
        low single-digit royalties on potential sales of GSK&#8217;s malaria vaccine.
      </li>
      <li style="margin-bottom: 10.0px">
        File Investigational New Drug (IND) applications for two checkpoint
        modulator antibody programs, one of which is part of our alliance with
        Incyte.
      </li>
      <li style="margin-bottom: 10.0px">
        Leverage Agenus capabilities through further corporate partnerships.
      </li>
    </ul>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Conference Call and Web Cast Information</b>
    </p>
    <p>
      Agenus executives will host a conference call at 11:00 a.m. Eastern Time
      today. To access the live call, dial 1-866-233-4585 (U.S.) or
      1-416-640-5946 (international). The call will also be webcast and will
      be accessible from the company&#8217;s website at <u>www.agenusbio.com/webcast/</u>.
      A replay will be available on the company&#8217;s website approximately two
      hours after the call and will remain available for 60 days. The replay
      number is 1-866-245-6755 (U.S.) 1-416-915-1035 (international), and the
      access code is 857826.
    </p>
    <p>
      <b>About Agenus</b>
    </p>
    <p>
      Agenus is an immunology company discovering and developing novel
      checkpoint modulators, vaccines and adjuvants to treat cancer and other
      diseases. Using its proprietary platforms Retrocyte Display<sup>TM</sup>
      and SECANT&#174;, the Company is discovering and developing novel antibodies
      to target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed
      checkpoints in partnered and internal programs. Agenus&#8217; heat shock
      protein vaccine, Prophage, has successfully completed Phase 2 studies in
      newly diagnosed glioblastoma multiforme. The Company&#8217;s QS-21 Stimulon&#174;
      adjuvant is extensively partnered with GlaxoSmithKline plc and Janssen
      Sciences Ireland Uc, and two vaccine candidates containing QS-21 have
      successfully completed Phase 3 trials. For more information, please
      visit <u>www.agenusbio.com</u>, or follow the company on Twitter
      @Agenus_Bio; information that may be important to investors will be
      routinely posted in these locations.
    </p>
    <p>
      <b>Forward-Looking Statement</b>
    </p>
    <p>
      <i>This press release contains forward-looking statements that are made
      pursuant to the safe harbor provisions of the federal securities laws,
      including statements regarding Agenus&#8217; target milestones for 2015. These
      forward-looking statements are subject to risks and uncertainties that
      could cause actual results to differ materially. These risks and
      uncertainties include, among others, the factors described under the
      Risk Factors section of our Prospectus Supplement filed with the
      Securities and Exchange Commission on May 21, 2015. Agenus cautions
      investors not to place considerable reliance on the forward-looking
      statements contained in this release. These statements speak only as of
      the date of this press release, and Agenus undertakes no obligation to
      update or revise the statements, other than to the extent required by
      law. All forward-looking statements are expressly qualified in their
      entirety by this cautionary statement.</i>
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; width: 100%; font-family: Times New Roman; font-size: 8pt" cellspacing="0">
      <tr>
        <td colspan="17">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" colspan="17" valign="top">
          <b>Summary Consolidated Financial Information</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" colspan="17" valign="top">
          <b>Condensed Consolidated Statements of Operations Data</b>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" colspan="17" valign="top">
          (in thousands, except per share data)
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" colspan="17" valign="top">
          (unaudited)
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="7" valign="top">
          Three months ended June 30,
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="7" valign="top">
          Six months ended June 30,
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center; padding-right: 0.0px; white-space: nowrap" colspan="3" valign="bottom">
          2015
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center; padding-right: 0.0px; white-space: nowrap" colspan="3" valign="bottom">
          2014
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center; padding-right: 0.0px; white-space: nowrap" colspan="3" valign="bottom">
          2015
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center; padding-right: 0.0px; white-space: nowrap" colspan="3" valign="bottom">
          2014
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Revenue
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          6,377
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          3,074
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          10,330
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          3,795
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Operating expenses:
        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="padding-left: 5.0px; text-align: left" valign="top">
          Research and development
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          24,773
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          5,223
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          33,993
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          9,695
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="padding-left: 5.0px; text-align: left" valign="top">
          General and administrative
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          8,016
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          5,847
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          13,503
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          11,290
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="padding-left: 5.0px; text-align: left" valign="top">
          Non-cash contingent consideration fair value adjustment
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          6,783
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          224
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          14,321
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          1,133
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Operating loss
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (33,195
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (8,220
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (51,487
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (18,323
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Other (expense) income, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (7,215
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          458
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (7,665
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          9,924
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Net loss
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (40,410
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (7,762
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (59,152
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (8,399
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Dividends on Series A-1 convertible preferred stock
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (51
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (51
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (101
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (102
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt" colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left; padding-bottom: 4.0px" valign="top">
          Net loss attributable to common stockholders
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (40,461
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (7,813
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (59,253
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (8,501
        </td>
        <td style="padding-left: 0.0px; border-bottom: double black 2.25pt; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Per common share data, basic and diluted:
          </p>
        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="padding-left: 15.0px; text-align: left" valign="top">
          Net loss attributable to common stockholders
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (0.53
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (0.12
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (0.83
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          (0.15
        </td>
        <td style="padding-left: 0.0px; text-align: left; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td style="padding-left: 15.0px; text-align: left" valign="top">
          Weighted average number of common shares outstanding, basic and
          diluted
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          76,375
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          62,608
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          71,548
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          56,616
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; width: 100%; font-family: Times New Roman; font-size: 8pt" cellspacing="0">
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td colspan="5">

        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="5" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Condensed Consolidated Balance Sheet Data</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="5" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (in thousands)
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: center" colspan="5" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (unaudited)
          </p>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="2">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="2">

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center" colspan="2" valign="top">
          June 30, 2015
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; border-bottom: solid black 1.0pt; text-align: center" colspan="2" valign="top">
          December 31, 2014
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="2">

        </td>
        <td>

        </td>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Cash, cash equivalents and short-term investments
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          139,642
        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          $
        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          40,224
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Total assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          180,110
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          74,527
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; text-align: left" valign="top">
          Total stockholders' equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          87,190
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="padding-left: 0.0px; text-align: right; padding-right: 0.0px; white-space: nowrap" valign="bottom">
          23,018
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      CONTACT:<br><b>Media:<br></b>Brad Miles, 646-513-3125<br>BMC
      Communications<br><u>bmiles@bmccommunications.com</u><br>or<br><b>Investors:</b><br>Andrea
      Rabney/Jamie Maarten, 212-600-1902<br>Argot Partners<br><u>andrea@argotpartners.com</u><br><u>jamie@argotpartners.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
